Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Idamycin PFS, Zavedos
Idarubicin is an anthracycline antineoplastic agent used to treat various types of leukemia. It belongs to the class of anthracycline antibiotics and functions by interfering with DNA and RNA synthesis, ultimately leading to cell death. Idarubicin is an analog of daunorubicin and is more potent.
Used to treat acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), and some other cancers.
Idarubicin can cause severe, potentially life-threatening myelosuppression (decreased production of blood cells) including neutropenia and thrombocytopenia. Idarubicin can also cause cardiomyopathy, particularly cumulative doses. Monitor blood counts and cardiac function closely.
Outcome:
Increased risk of cardiotoxicity
Mechanism:
Synergistic cardiotoxic effects
Outcome:
Increased idarubicin exposure
Mechanism:
Inhibition of idarubicin metabolism
Outcome:
Decreased idarubicin absorption
Mechanism:
Unknown
Most likely new formulation: Liposomal idarubicin for improved efficacy and reduced cardiotoxicity (2025, 80% confidence)
Based on current clinical trial data and usage trends, there is a 70% likelihood of expanded indications for idarubicin in other hematological malignancies within the next 5 years.
Antineoplastic, Anthracycline Antibiotic
Anthracycline